Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022
Royalty Pharma (RPRX) will report its fourth-quarter and full-year 2021 financial results on February 15, 2022, before market opening. The company will host a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, founded in 1996, is a major player in biopharmaceutical royalties, partnering with various organizations to fund innovation. Its portfolio includes royalties on over 40 commercial products from leading pharmaceutical companies, showcasing its extensive involvement in the sector.
- Royalty Pharma to report financial results on February 15, 2022.
- Strong portfolio with royalties on over 40 commercial products.
- None.
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 6819125.
A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
When will Royalty Pharma announce its fourth-quarter and full-year 2021 financial results?
What time will the conference call for Royalty Pharma's financial results occur?
How can investors access the live webcast of Royalty Pharma's conference call?
What is Royalty Pharma's business model?
